Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. (NTRBW) delivers innovative transdermal solutions addressing critical pharmaceutical safety challenges through its proprietary AVERSA® technology. This dedicated news hub provides investors and industry stakeholders with essential updates about regulatory progress, product development milestones, and strategic partnerships.
Access real-time announcements covering clinical trial developments, intellectual property expansions, manufacturing agreements, and consumer product launches. Our curated feed includes earnings reports, FDA submission updates, and analysis of technologies combating opioid misuse through abuse-deterrent systems.
Key focus areas include advancements in transdermal drug delivery systems, international patent grants, and collaborations with industry leaders like Kindeva Drug Delivery. Stay informed about Nutriband's progress in integrating Bitrex®-based safety mechanisms across therapeutic applications while maintaining compliance with global regulatory standards.
Bookmark this page for verified updates about Nutriband's mission to enhance medication safety through cutting-edge transdermal innovations. Monitor critical developments in pharmaceutical abuse prevention and topical delivery systems from a single authoritative source.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is hosting an exclusive live investor webinar and Q&A session on July 25, 2024, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature Chairman and President Serguei Melnik and CEO Gareth Sheridan discussing current operations and upcoming milestones.
Nutriband is focusing on addressing the global opioid crisis with its AVERSA™ abuse-deterrent transdermal technology. Their lead product, AVERSA™ Fentanyl, is targeting peak annual sales of $80 million to $200 million upon FDA approval. The company is pursuing a streamlined 505(b)(2) NDA regulatory pathway, requiring only a single Phase 1 trial with potential for an expedited six-month FDA review.
Nutriband Inc. (NASDAQ:NTRB) has received a Notice of Allowance from the USPTO for its AVERSA™ trademark, a key component of its abuse-deterrent transdermal patch technology. The company's lead product, AVERSA™ Fentanyl, is progressing towards commercial manufacturing scale-up in partnership with Kindeva Drug Delivery. Nutriband plans to file an IND application with the FDA, preceding pivotal studies to demonstrate the abuse-deterrent properties of AVERSA™ Fentanyl.
The upcoming human abuse potential study will compare AVERSA™ Fentanyl to a current fentanyl patch without abuse-deterrent features. Preliminary studies indicate AVERSA™ technology's high resistance to manipulation. A market analysis projects potential peak annual U.S. sales of $80 million to $200 million for AVERSA™ Fentanyl, highlighting its significant market potential in abuse-deterrent pharmaceuticals.
Nutriband has provided an update on its Aversa Fentanyl product development program. The company, in collaboration with Kindeva Drug Delivery, has progressed in developing the commercial manufacturing process for a transdermal fentanyl patch incorporating Nutriband's AVERSA™ abuse-deterrent technology. This follows a feasibility agreement and a commercial development and clinical supply agreement between the two companies.
Kindeva has validated analytical methods for handling aversive agents required for the product. Nutriband plans to file an Investigational New Drug (IND) application with the FDA, including chemistry, manufacturing, and clinical study protocols for a Phase 1 human abuse potential study, which is pivotal for the New Drug Application (NDA) process. No Phase 2 or Phase 3 trials are needed.
The AVERSA Fentanyl patch aims to prevent drug misuse while ensuring accessibility for patients in need, with potential peak annual US sales estimated between $80 million to $200 million.
Nutriband reported Q1 revenues of $408,532, highlighting a 219% YoY increase in sports tape sales via its Pocono Pharma subsidiary. The company is leveraging penetration pricing to secure deals with major brands like KT Tape, Reebok, Adidas, and New Balance.
In Q1, Nutriband completed an $8.4M private placement at $4 per share, bringing its cash position to $8,347,739 as of April 30, 2024.
The company is advancing its AVERSA line, targeting a Q1 2025 NDA filing for AVERSA Fentanyl, projected to achieve peak annual sales of $80-$200M. AVERSA Buprenorphine could reach up to $130M in annual sales.
Nutriband (NASDAQ:NTRB), a developer of transdermal pharmaceuticals and technology, will host an exclusive live investor webinar on May 30, 2024, at 4:15 p.m. ET.
Organized by RedChip Companies, the event will feature Chairman Serguei Melnik and CEO Gareth Sheridan, who will provide insights into the company's current operations and future milestones.
Investors can register for the free webinar and submit questions beforehand or during the live session.
Nutriband announced the appointment of Sergei Glinka to its board of directors. Glinka, an experienced business leader, brings a wealth of experience from his roles in major European companies. The Glinka family has invested $4.5 million in Nutriband via a private placement in April 2024, which totaled $8.4 million. Nutriband aims to use these funds to complete the FDA approval process for its AVERSA™ technology. AVERSA™, currently patented in 45 countries, is projected to reach peak annual US sales between $80 million and $200 million. The global opioid market was valued at $22.8 billion in 2022.
FAQ
What is the current stock price of Nutriband (NTRBW)?
